Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hormones
Published in: Hormones 3/2011

01-07-2011 | Review

Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis

Authors: Konstantinos A. Toulis, Athanasios D. Anastasilakis, Stergios A. Polyzos, Dr. Polyzois Makras, MD, PhD

Published in: Hormones | Issue 3/2011

Login to get access
Metadata
Title
Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis
Authors
Konstantinos A. Toulis
Athanasios D. Anastasilakis
Stergios A. Polyzos
Dr. Polyzois Makras, MD, PhD
Publication date
01-07-2011
Publisher
Springer International Publishing
Published in
Hormones / Issue 3/2011
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI
https://doi.org/10.14310/horm.2002.1308

Other articles of this Issue 3/2011

Hormones 3/2011 Go to the issue

Research paper

The response of serum leptin, cortisol and zinc concentrations to concurrent training

Case Report

Growth Hormone Deficiency: an unusual presentation of Floating Harbor Syndrome

Case Report

Late diagnosis of 5alpha steroid-reductase deficiency due to IVS12A>G mutation of the SRD5a2 gene in an adolescent girl presented with primary amenorrhea

Historical note

Obesity in the paleolithic era

Research paper

Cushing’s disease: Results of treatment and factors affecting outcome

Review

Sexual dysfunction in diabetic women
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits